Atara Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $134.70M
- P/E (TTM)
- 3.5
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | $600.00K | $-0.32 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 16, 2026 | During market hours | – | $-0.25 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $3.50M | $-0.32 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | During market hours | $17.60M | $0.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $98.10M | $3.50 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 7, 2025 | During market hours | $32.75M | $-1.19 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $40.20M | $-2.93 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | During market hours | $28.60M | $-3.10 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 1, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating expenses | full-year 2025 | 60% growth | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Atara Biotherapeutics filed with the SEC
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides a Business Update
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO
Results of operations · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel
Results of operations · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO TM (tabelecleucel)
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO TM (tabelecleucel) and ATA3219
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO TM (tabelecleucel)
Results of operations · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Results of operations · Executive or director change · EX-99.1 to Form 8-K
This Securities Purchase Agreement (this Agreement ) is dated as of September 3, 2024, between Atara Biotherapeutics,
Executive or director change · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Investor presentation 42nd Annual j.p.
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the
Exit or restructuring costs · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel ® Partnership with Pierre Fabre Laboratories
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Expanded Global Tab-cel ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
Material agreement · Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Plans to Submit Tab-cel ® BLA in Q2 2024 Following
Other events · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
Results of operations · Executive or director change · EX-99 to Form 8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
Material agreement · Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
Material agreement · Results of operations · Executive or director change · EX-99.1 to Form 8-K
Ola EBV+ PTLD Advocate ATARA BIO® Investor Presentation JP Morgan Healthcare Conference January 10, 2022 Nasdaq: ATRA
Regulation FD disclosure · EX-99.1 to Form 8-K
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
Results of operations · EX-99.1 to Form 8-K